Regulatory Momentum Builds for ADCs in Solid Tumor Oncology

Regulatory momentum for antibody-drug conjugates (ADCs) in aggressive lung cancers is accelerating, as GSK advances its B7-H3-targeted candidate risvutatug rezetecan (or Ris-Rez) into additional global orphan drug pathways for small-cell lung cancer (SCLC). In March 2026, the investigational ADC received orphan drug designation from Japan’s Ministry of Health, Labor and Welfare for the treatment of SCLC, supported by early clinical data demonstrating durable responses in patients with extensive-stage SCLC (ES- SCLC).

The designation marks the sixth global regulatory recognition for the program, which reinforces its positioning within a growing class of targeted cytotoxic therapies for difficult-to-treat solid tumors, according to GSK in a March 23, 2026 announcement.¹

SCLC remains a high unmet need, particularly ES-SCLC, in which the cancer has spread throughout one or both lungs and/or to other parts of the body.² In ES-SCLC, relapse rates are high and treatment options are limited. Median overall survival remains approximately 8 months with current standard-of-care therapies, underscoring the need for novel approaches capable of improving durability of response.³

How are B7-H3-targeted ADCs addressing treatment gaps in SCLC?

Ris-Rez is designed to target B7-H3, an immune checkpoint molecule broadly expressed across multiple solid tumors, including SCLC.⁴ The ADC consists of a fully human monoclonal antibody linked to a topoisomerase inhibitor payload, enabling targeted delivery of cytotoxic therapy to tumor cells.

This mechanism aims to improve therapeutic selectivity while minimizing systemic toxicity, a key limitation of conventional chemotherapy. Early-phase clinical findings from a phase 1 study (ARTEMIS-001) indicated durable responses in patients with ES-SCLC, supporting continued clinical development.⁵

The program has progressed into a global phase 3 trial evaluating its efficacy in relapsed ES-SCLC, reflecting increased confidence in the target and modality. Beyond lung cancer, the ADC candidate is being investigated across additional tumor types, including prostate and colorectal cancers, highlighting the broader applicability of B7-H3 as a therapeutic target, according to the company.

What does orphan designation signal for ADC development strategies?

Orphan drug designation provides regulatory incentives, including development support and potential market exclusivity, which may help accelerate clinical and commercial pathways for therapies targeting rare or high-need populations.

For ADCs, such designations increasingly serve as validation of early clinical activity and mechanistic rationale, particularly in cancers with limited treatment innovation. The accumulation of multiple designations across regions, including the United States and Europe, signals alignment among regulatory agencies regarding the potential clinical impact of the therapy.

In addition to Japan’s designation, Riz-Rez has received orphan status from the FDA and the European Medicines Agency, as well as priority medicines (PRIME) and breakthrough therapy designations in specific indications. These designations collectively support expedited development pathways and may facilitate earlier regulatory engagement.¹

Can ADC innovation improve outcomes in aggressive solid tumors?

The continued advancement of ADCs targeting novel antigens such as B7-H3 reflects a broader shift toward precision-guided cytotoxic therapies in oncology. By combining tumor-specific targeting with potent payloads, ADCs aim to enhance efficacy while reducing off-target effects.⁴

In SCLC, where disease progression is rapid and therapeutic options are limited following relapse, such approaches may offer meaningful improvements in response durability and survival outcomes. However, confirmatory data from late-stage clinical trials will be critical to establish clinical benefit and define positioning within treatment paradigms.⁶

As ADC pipelines expand, the integration of novel targets, improved linker technologies, and optimized payloads is expected to further refine this therapeutic class. The advancement of Riz-Rez into multiple regulatory pathways underscores the growing role of ADCs in addressing persistent gaps across solid tumor oncology.

References

1. GSK. GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan. Published March 23, 2026. Accessed March 24, 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-risvutatug-rezetecan-granted-orphan-drug-designation-for-small-cell-lung-cancer-in-japan/
2. National Cancer Institute. SEER Explorer Surveillance Research Program. Accessed March 24, 2026. https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on#resultsRegion0
3. Mountzios G, Sun L, Cho BC, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N. Engl. J. Med. 2025;393(4):349-361. doi: 10.1056/NEJMoa2502099 
4. Ma Y, Yang Y, Huang Y, et al. A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial. Nat. Med. 2025;31:1949-1957. doi: 10.1038/s41591-025-03600-2
5. Duan J, Sun Y, Wang Q, et al. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial. Cancer Cell. 2026;S1535-6108(26)00104-2. doi: 10.1016/j.ccell.2026.02.006
6. Syal A, Meyer M-L, Angelino K, et al. Antibody drugs conjugates in small-cell lung cancer: present-day status and promises. The Oncologist 2025;30(11): oyaf332. doi: 1093/oncolo/oyaf332